• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Liposome-based anchoring and core-encapsulation for combinatorial cancer therapy

    2022-09-15 03:10:50QingqingXiaoXiaotongLiChangLiuYiYangYuqiHouYingWangMengxiangSuWeiHe
    Chinese Chemical Letters 2022年9期

    Qingqing Xiao, Xiaotong Li, Chang Liu, Yi Yang, Yuqi Hou, Ying Wang, Mengxiang Su,Wei He

    School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

    ABSTRACT Downregulated pro-apoptotic protein in cancer cells compromises the chemotherapy by a cytotoxic drug.Here, we report co-delivery of a pro-apoptotic protein, caspase 3 (Cas 3), and cytotoxic agent, oridonin(ORD), for synergistic cancer treatment, using a method of liposome-based anchoring and core encapsulation.First, ORD is modified with hyaluronic acid (HA) to improve its solubility.Then, the targeted codelivery system is prepared by assembling the conjugate HA-ORD onto the Cas 3-loaded liposomes, which the surface HA can target the CD44 receptor on cancer cells. In vitro, the co-loaded liposomes (120 nm)are specifically taken up by 4T1 cells and endow a 1.5-fold increase of Cas 3.After intravenous injection into the tumor-bearing mice, the liposomes accumulate in the tumor with high efficacy and significantly inhibit tumor growth via promoting apoptosis and anti-proliferation of cancer cells.Mechanistically, the co-delivery works synergistically by upregulating the activated Cas form, cleaved-Cas 3.

    Keyword:Liposomes Co-delivery Chemotherapy Pro-apoptotic protein Tumor targeting

    Breast cancer was the most commonly diagnosed cancer globally, accompanying approximately 2.26 million cases [1].The cancer occurrence mainly results from cell apoptosis disorder, which inhibits pro-apoptotic signals in tumor cells while anti-apoptotic proteins are upregulated.Two initiation pathways are frequently involved in cell apoptosis: activating death receptors through external damage and triggering the release of cytochrome c and other substances from the mitochondria via intrinsic pathways [2].Clinical evidence shows that the combination of traditional chemotherapy and pro-apoptotic agents can synergistically elevate the survival rate of cancer patients [3].Furthermore, caspase 3 (Cas 3)is a significant mediator of cancer cell apoptosis after exposure to cytotoxic drugs or radiotherapy [4,5].Therefore, we theorized that combinatorial use of Cas 3 and the cytotoxic drug could represent a promising regimen to combat cancer.

    Poor drug delivery to the tumor site is a significant limitation that hinders cancer treatment.Drug carriers can improve tumor targeting because of their small size and penetration inside the diseased area [6].Liposomes (Lips) are enclosed spherical vesicles composed of one or more lipid bilayers [7].Lips are emerging as promising carriers to enhance drug delivery due to the advantages, including high payload capacity, prolonged blood circulation time, targeting ability to the disease site, and ignorable toxicity to the body [8–10].Over 20 liposomal formulations were approved for clinical use [11].In this study, we co-delivered oridinon (ORD) and Cas 3 using Lips for the combined treatment of breast cancer in 4T1 tumor-bearing mice.ORD is a natural compound with poor solubility isolated from the traditional Chinese medicine Rubescenin [12].It has a robust ability to fight against various cancers such as liver cancer, prostate cancer, and breast cancer [13–17].Briefly, ORD was conjugated with hyaluronic acid(HA) to improve its solubility.After that, the co-delivery system,hybrid nanoparticles (HNPs), was prepared by assembling the HAORD conjugate onto the Cas 3-loaded liposomes, which the conjugate hydrophobic segment anchored into the liposomal membrane and, meanwhile, the HA part located on the HNPs surface to target CD44 receptor on cancer cells (Scheme 1) [18,19].The targeted co-delivery system efficiently accumulated in the tumor and inhibited the tumor growth synergistically through upregulation of the activated Cas 3 form, cleaved-Cas 3.

    Scheme 1.(A) Preparing the co-delivery system (HNPs) by anchoring the conjugate HA-ORD onto Cas 3-Lips.(B and C) Purposed performance in vivo.After intravenous injection, (B) HNPs accumulate in the tumor, and (C-1) target tumor cells through CD44-HA receptor-ligand interaction, (C-2) release the two active ingredients inside the cells, and (C-3) synergistically activate Cas-3 pathway to promote apoptosis of tumor cells.

    First, the conjugate HA-ORD was synthesizedviaesterification reaction as described in previous report [20].Cas 3-Lips were prepared by the reverse-phase evaporation method [21].As depicted in Table S1 (Supporting information), the protein-encapsulated Lips have a diameter of 120 nm and a protein encapsulation efficacy(EE) of greater than 50% in the formulations with protein/lipid ratios (w/w) of 1:10–1:30.The protein encapsulation was identified by SDS-PAGE, in which the demulsification separated protein bands significantly weakened compared with the control (Fig.1A).The protein/lipid ratios had a modest influence on the diameter and EE; however, the ratio increase reduced the drug-loading capacity from approximately 5% to 2%.Accordingly, the Lip formulation with a protein/lipid ratio of 1:10 was selected for further study due to its highest drug payload.Then, the co-delivery system, HA-ORD/Cas 3-Lip HNPs, was prepared by assembling the conjugate onto the Cas 3-Lips.The particle size of HNPs increased from 113 nm to 274 nm with a gradual decrease in the zeta potential as HA/lipid ratio elevated from 1:4 to 2:1 (w/w) (Table S2 in Supporting information).To investigate the co-assembly, we conducted the FRET study for the HNPs with various HA/lipid mass ratios by using FITC as a donor conjugated with HA-ORD and Rho as the acceptor encapsulated in the Lips.With the increase of Rho-Lips in the HNPs,the maximal fluorescence intensity of the acceptor (Rho) at 575 nm increased significantly.In comparison, the maximal fluorescence intensity of the donor (FITC) at 515 nm decreased, indicating the FRET occurrence (Fig.1B).FRET is a potent tool for studying the interaction between two materials by labeling fluorescent donor and acceptor [22–24].Consequently, the assembly of the conjugate and the Lips was confirmed.

    The HNPs with the HA/lipid ratio of 1:2 were selected for further study due to the smaller diameter (~118 nm) and higher loading of Cas 3.TEM test displayed that the Lips and HNPs had spherical morphology (Fig.1C).The drug EE% and DL% in total in HNPs was 48.75% and 7.92%, respectively, which the DL% of Cas 3 and ORD was 4.75% and 3.17%, respectively.Incubation in 10% serum for 12 h imposed a slight alteration in diameter, surface charge, and morphology of the two nanoparticles (Figs.1D–F).However, their PDI and surface potential gradually increased during the incubation period of 12–24 h.It is worth noting that these increase from HNPs was compromised compared with Lips.The data demonstrated that the conjugate assembly could improve the serum stability of Lips.Release study shows that 60%–80% of encapsulated dye carboxyfluorescence (CF) in the core of liposomes from HNPs was released at 2 h under different pH conditions (Fig.1G), indicating that HNPs can effectively release the encapsulated drug.Meanwhile, the HAORD release from HNPs was pH-dependent, increasing pH value resulting in a faster release.Interestingly, the release at pH 5 was significantly slower than at pH 6.8 and 7.4.The profile demonstrated that the conjugate has an elevated force to anchor onto liposome under low pH conditions and might help maintain the structural stability of HNPs in the acidic tumor microenvironment (Fig.1H).

    Next, the uptake study in 4T1 cells was performed by flow cytometry.As displayed in Figs.S1 and S2 (Supporting information),the uptake of the conjugate and the two nanoparticles was timedependent in a specific period.Especially, HNPs reached their maximal uptake at 1 h after incubation, while Lips did not get the most significant uptake at even 4 h (Fig.S1B), indicating faster endocytosis of HNPs.The further experiment showed that the uptake of HNPs was concentration-dependent (Figs.S1C and D).

    Fig.1.Characterization: (A) SDS PAGE of free Cas 3 and separated Cas 3 after Cas 3-Lips demulsification.(B) Fluorescence emission spectra of FITC-HA-ORD, Rho-Lips and FITC-HA-ORD/Rho-Lip HNPs with various HA/lipid mass ratios. λex=450 nm.(C) TEM images of Cas 3-Lips and HA-ORD/Cas 3-Lip HNPs.The scale bar is 100 nm.(D and E)Serum stability of Lips and HNPs in 10% FBS at 37°C.The change of the (D, E) morphology, size, PDI, and (F) ζ-potential of Lips and HNPs.(G) In vitro release of CF from CF-labeled HNPs at 37°C.CF was encapsulated in the cores of HNPs.(H) In vitro release of FITC-HA-ORD from HNPs.Data are presented as mean ± SD (n=3).The samples collected at specified time intervals were placed in a 96-well plate to measure fluorescence intensity using a fluorescence spectrometer (CF, λex=492 nm and λem=515 nm;FITC, λex=490 nm and λem=520 nm).

    The CD44 receptor is overexpressed on various tumor cells [25],and HA is a specific ligand for CD44 [26–28].To verify CD44 role in HNPs uptake, we saturated the surface CD44 receptors by preincubating 4T1 cells with excess free HA.Flow cytometry assay showed that Rho-HNPs uptake in the pretreated cells was significantly reduced compared with unsaturated cells (P<0.05, Fig.S1E).Laser scanning confocal microscope (CLSM) observation indicated HA pretreatment resulted in weaker intracellular fluorescence intensity (Fig.S1F).To further prove the targetability of HNPs to cancer cells, we investigated the uptake in 4T1 cells and the control cell line without over-expressing CD44 receptors, NIH 3T3.As expected, the uptake of HNPs in 4T1 cells was significantly higher than that in NIH 3T3 cells under fixed FITC or Rho concentration conditions (Figs.S1G and H).These results confirmed that the conjugate anchoring promoted the Lips uptake in tumor cells through the specific HA/CD44 ligand/receptor affinity.

    To test the anti-tumor activity, we incubated preparations with 4T1 cells.Cas 3-Lips display improved cytotoxicity to 4T1 cells at the protein concentrations of ≥2.5 μg/mL compared with free Cas 3 (Fig.S3A in Supporting information), owing to that liposome encapsulation can improve the protein stability and promote the uptake.The conjugate HA-ORD had concentration-dependent cytotoxicity.The ORD in the conjugate could be released due to the ester-bond degradation by the cytosol esterase [29].Therefore, the conjugate HA-ORD demonstrated toxicity against cancer cells.In contrast, HNPs showed the most profound cytotoxicity among the preparations at specific drug concentrations (31.3 μg/mL, Fig.S3B in Supporting information), accompanied with a 2-fold cytotoxicity increase in contrast with the simple combination of Cas 3 and the conjugate.

    The synergy effect was investigated by measuring the cytotoxicity of HNPs with different mass ratios of HA/lipid (2:1, 1:1, 1:2,1:4) and calculating the combination index (CI) by Compusyn software.The CI values from formulations with ratios of 2:1, 1:1, 1:2 are<1 at a specific low inhibition rate (Fa), while, at all Fa, the CI from 1:4 ratio is not great than 1 (Figs.S3C and D in Supporting information), indicating its improved synergy.As a result, the HNPs with HA/lipid of 1:4 were selected for further study.

    Apoptosis determination displayed that HA-ORD and Cas-Lips had 60% and 10% of 4T1 cell apoptosis after 48 h incubation.However, the simple combination formulation did not lift the apoptosis rate (60%) compared with HA-ORD.In contrast, HNPs exhibited an 83% apoptosis rate and thus indicated the co-delivery allowed enhanced apoptosis of cancer cells (Figs.S3E and F in Supporting information).

    Then, the level of critical proteins in the apoptosis process was determined by WB.Cas 3 exists in an inactive precursor form in cells.After being activated, it is cleaved at an aspartate and is broken down into cleaved-Cas 3 [30].Finally, cleaved-Cas 3 initiates the downstream protein pathway or blocks DNA repair to induce cell apoptosis [31–33].Therefore, we determined the expression level of Cas 3 and cleaved-Cas 3 after preparation incubation.As depicted in Fig.2, the dosing with HNPs endorsed the highest level of Cas 3 and cleaved-Cas 3 in tumor cells, verifying the intracellular delivery of Cas 3 and its activation.Also, the conjugate induced Cas 3 expression and implied its potential ability to promote tumor cell apoptosis.

    Fig.2.Expression of the pro-apoptotic protein in 4T1 cells: (A) WB analysis of Cas 3 and cleaved-Cas 3 expressions in cells after treatment with preparation for 48 h at an ORD concentration of 0.5 mg/mL or Cas 3 concentration of 10 μg/mL. β-Actin was used as a loading control.Dark bands indicate protein expression.Quantitative analysis of the expression of (B) Cas 3 and (C) cleaved-Cas 3.mean ± SD, n=3, ?P<0.05, ??P<0.01, ???P<0.001.Preparations: 1, saline; 2, free Cas 3; 3, HA-ORD; 4, HNPs.

    To study the biodistribution, we labeled fluorescence probe DiR (DiIC 18 (7); 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide) to the nanoparticles for imaging [34].After intravenous injection,in vivoimaging of 4T1 tumor-bearing mice at specific time points was executed.Both DiR-Lips and DiR-labeled HNPs effectively accumulated at the tumor site for 24 h period compared with free DiR (Fig.3).Whereas the tumor accumulation of DiR-labeled HNPs, especially at 24 h post-injection, was greater than that of DiR-Lips (P<0.05,Fig.3C).Ex vivoimaging for separated major tissues collected at 24 h further verified that DiR-labeled HNPs had improved tumortargeting ability over DiR-Lips (Fig.3B).These results indicated that the conjugate anchoring promoted the tumor accumulation of Lips and prolonged the residence time.

    Fig.3.Tumor targeting in vivo: (A) In vivo fluorescence imaging of 4T1 tumor-bearing mice after i.v.injection of DiR-labeled preparations at the dye dose of 0.5 mg/kg,according to the body weight.(B) Ex vivo fluorescence images of important tissues were collected at 24 h post-injection.(C) Quantitative analysis of tumor accumulation at different time points (n=3, ?P<0.05, ??P<0.01).

    To study the anti-tumor efficacy, we intravenously administered different preparations to 4T1 tumor-bearing mice every 3 days for 5 doses in 18 days.The tumor volume at 18 days in the salineor free Cas 3-treated group increased by>10-fold compared to that at 0 day, while the tumor volumes in the group treated with HA-ORD group or the physical mixture (free Cas 3 plus HA-ORD)group has 7-fold growth.Significantly, the tumor volume from the groups dosed with HNPs at low or high does exhibited a 5-fold increase and demonstrated significant tumor growth inhibition (Fig.4A).The animal’s body weight in all groups did not decline and,instead, increased at a steady rate (Fig.4B).These results indicated that HA-ORD and HNPs safely regressed the tumor growth in 4T1 tumor-bearing mice, whereas HNPs had improved inhibition.

    The cancer-cell apoptosis in the isolated tumors was examined by TUNEL and Ki67 assay [35].Positive cells shown in TUNELstained sections were most profound in the groups treated with high or low doses of HNPs, followed by the groups treated with preparations containing HA-ORD (Fig.S4 in Supporting information).Quantified determination displayed that HNPs treatment allowed a 50% apoptosis rate in the tumor cell, 5 folds as great as saline treatment.The apoptosis rate of the two groups dosed with preparations containing HA-ORD, HA-ORD, and physical mixture, reached 30% as well (Fig.4C).The apoptosis result was confirmed by the anti-proliferation determination by Ki67 assay (Fig.4D and Fig.S4).The H&E staining assay further demonstrated that the fewest cell numbers were observed in the tumor treated with HNPs (Fig.S4).

    Fig.4. In vivo anti-tumor activity: (A) Tumor-volume growth curves and (B) body-weight change profiles of 4T1 tumor-bearing mice (mean ± SD, n=7).Quantitative analysis of (C) apoptosis and (D) proliferation of tumor cells (mean ± SD, n=3).(E) Western blot analysis of Cas 3 and cleaved-Cas 3 expression in the isolated tumors.Preparations:1, saline; 2, free Cas 3; 3, HA-ORD; 4, physical mixture of Cas 3 and HA-ORD; 5, HNPs. β-Actin was used as a loading control.Dark bands indicate protein expression.Quantified expression of (F) Cas 3 and (G) cleaved-Cas 3 (mean ± SD, n=3).The preparations (0.2 mL) were injected to 4T1 tumor-bearing mice via tail veins every 3 days at an ORD dose of 5 mg/kg or a Cas 3 dose of 150 μg/kg, according to the body weight.HNPs were administrated at two doses of ORD/Cas 3, 5 mg/150 μg/kg, and 7.5 mg/225 μg/kg.?P<0.05, ??P<0.01, ???P<0.001.

    We hypothesized that the tumor-suppressor effect of HNPs was directly related to the delivery and activation of Cas 3.Accordingly,the protein in the isolated tumors was determined by WB assay.Administration with low dose HNPs increased the Cas 3 level by 50% compared with treatment with other preparations (P<0.05,Figs.4E and F).Moreover, the activated Cas 3 form, cleaved-Cas 3,in the group dosed with low dose HNPs raised by approximately 2 folds compared to that from the saline-treated group (P<0.001,Figs.4E and G).The results indicated that the HNPs could effectively deliver Cas 3 into the tumor.

    Overall, HNPs played a significant therapeutic role in the 4T1 breast cancer model by inhibiting tumor growth and promoting tumor cell apoptosis.

    In this study, we demonstrated that the liposome-anchored strategy was promising to promote the co-delivery of active components with high molecular weight.Co-delivery of small molecular drugs using drug carriers has obtained breakthroughs, as evident by the approval of Vyxeos liposomes co-loading daunorubicin and cytarabine to treat acute myeloid leukemia in 2017 [36].However, co-delivery of two molecules with a high molecular weight with carriers is still a considerable challenge due to their limited space for loading.To enlarge the loading space, researchers incorporated cationic materials, such as polyethyleneimine (PEI)and dioleoyl phosphatidyl ethanolamine, into the liposomes to condense the second macromolecular drug on the surface [37].Nonetheless, their incorporation often induces significant toxicity to the body and hinders the translation of the co-delivery system.Herein, we found that the strategy of liposome-based anchoring and core encapsulation enabled the co-delivery of the two active molecules without additional cationic materials.The functional protein was encapsulated in the core of liposomes and whereas the second drug-polymer macromolecule was anchored onto the liposomes via inserting the hydrophobic groups inside the lipid membrane.As well known, most drug-polymer or antibodydrug conjugate has hydrophobic side or residues on their structure [38].Consequently, we believe the current approach is a universal platform to co-deliver polymer-based conjugate/prodrug and biopharmaceuticals.

    The anchoring allowed the liposomes to have enhanced targeting ability to the tumor (Fig.3).HA-ORD-anchored liposomes possessed a 50% increase of tumor accumulation over the liposomes.The profound tumor accumulation is mainly ascribed to the ligand/receptor affinity of HA/CD44 that allowed HNPs to target the tumor tissueviapotentially overcoming the shear forces of blood flow [39,40].Moreover, the conjugate anchoring led to an increase in the negative charge of Lips (Table S2 in Supporting information) and, as a result, could potentially reduce the adhesion of blood proteins to nanoparticles, thereby protecting the nanoparticles from excessive exposure to blood proteins and extending the circulation time [41].Third, the congruence principle might also contribute to the tumor accumulation because HNPs have rich HA on their surface, while a large HA matrix distributes in the tumor.

    Various approaches were employed to improve the stability and performance of liposomesin vitroandin vivo, including nanoparticle-coating [42], polymer-stabilization by covalently linking a polymer to the head groups of lipids [43], and embedding liposomes inside another nanodevice [44].These reported strategies either impaired the biocompatibility of liposomes or limited their translation due to the complicated preparation process.A previous report indicated that the surface coating could reduce the membrane fluidity of liposomes and enhance liposome stabilityin vivo[45].The conjugate anchoring might decrease the membrane fluidity of liposomes as well.Consequently, our HA-based anchoring represents a promising strategy to improve the use of liposomes as drug carriers.

    Co-delivery of Cas 3 and ORD is promising to inhibit tumor growth.Cas 3 is the final apoptosis executor of cancer cells and is downregulated, which has become one critical restriction for chemotherapy in cancer treatment [46,47].Though the two therapeutics are entirely different in water solubility, molecular weight,and stability, the developed HNPs could co-load the Cas 3 and the cytotoxic ORD and precisely deliver them to cancer cells.The results displayed that the two therapeutics worked synergistically to combat cancer.The study offers a route to improve chemotherapy.

    In summary, a liposome-based anchoring and core encapsulation strategy enables targeted co-delivery of two therapeutics,the conjugate HA-ORD and Cas 3, to the tumor, allowing efficient anti-tumor activities by suppressing tumor growth and enhancing apoptosis of tumor cells.Moreover, the conjugate anchoring confers positively targeting ability on liposomes, expands their drugloading capacity, and provides the potential to facilitate the utilization of liposomes as drug carriers.

    Declaration of competing interest

    There are no conflicts to declare.

    Acknowledgments

    This work was supported by the National Natural Science Foundation of China (Nos.81872823, 81872833 and 82073782), the Double First-Class (No.CPU2018PZQ13) of the CPU, the Shanghai Science and Technology Committee (No.19430741500), the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine(No.zdsys-202103).

    Supplementary materials

    Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2022.01.083.

    91成人精品电影| 看免费av毛片| 18在线观看网站| 19禁男女啪啪无遮挡网站| 亚洲专区中文字幕在线| 亚洲va日本ⅴa欧美va伊人久久| 精品午夜福利视频在线观看一区 | 亚洲熟女精品中文字幕| 成人免费观看视频高清| 一个人免费看片子| 女人高潮潮喷娇喘18禁视频| 精品福利观看| 免费一级毛片在线播放高清视频 | 啦啦啦 在线观看视频| 777久久人妻少妇嫩草av网站| 免费一级毛片在线播放高清视频 | 国产av又大| 91成年电影在线观看| 天天躁狠狠躁夜夜躁狠狠躁| 免费在线观看视频国产中文字幕亚洲| 国产亚洲午夜精品一区二区久久| 中文欧美无线码| 大陆偷拍与自拍| 人妻 亚洲 视频| 午夜视频精品福利| 欧美性长视频在线观看| 欧美大码av| 欧美日韩福利视频一区二区| 王馨瑶露胸无遮挡在线观看| 69精品国产乱码久久久| 国产有黄有色有爽视频| 国产欧美日韩一区二区三| 纯流量卡能插随身wifi吗| 天天躁日日躁夜夜躁夜夜| 国产一区二区 视频在线| aaaaa片日本免费| 大香蕉久久成人网| 99精国产麻豆久久婷婷| 少妇精品久久久久久久| 亚洲精品中文字幕在线视频| 国产精品1区2区在线观看. | 捣出白浆h1v1| 男人舔女人的私密视频| 欧美国产精品va在线观看不卡| 精品国内亚洲2022精品成人 | 国产免费av片在线观看野外av| 丝袜在线中文字幕| 不卡av一区二区三区| 制服人妻中文乱码| 欧美黄色淫秽网站| 两性夫妻黄色片| 国产免费福利视频在线观看| 在线天堂中文资源库| 精品一品国产午夜福利视频| 999久久久国产精品视频| 97人妻天天添夜夜摸| 中文字幕高清在线视频| 欧美久久黑人一区二区| 久久精品成人免费网站| 久久久久精品人妻al黑| 国产一卡二卡三卡精品| 一边摸一边做爽爽视频免费| 一级毛片精品| svipshipincom国产片| 精品一区二区三区四区五区乱码| 久久天躁狠狠躁夜夜2o2o| 99国产综合亚洲精品| 亚洲精品粉嫩美女一区| 亚洲成人国产一区在线观看| 飞空精品影院首页| 婷婷成人精品国产| 久久久久久免费高清国产稀缺| 国产精品1区2区在线观看. | 性色av乱码一区二区三区2| 国产精品久久久人人做人人爽| 在线亚洲精品国产二区图片欧美| 老司机在亚洲福利影院| 精品久久久精品久久久| 人人妻人人添人人爽欧美一区卜| 婷婷丁香在线五月| 一区二区av电影网| tocl精华| 最近最新免费中文字幕在线| 黄色视频,在线免费观看| 精品乱码久久久久久99久播| 精品人妻1区二区| 欧美性长视频在线观看| 国产亚洲精品一区二区www | 免费人妻精品一区二区三区视频| 国产精品一区二区在线观看99| 一区二区日韩欧美中文字幕| 亚洲国产看品久久| 久久人人97超碰香蕉20202| 少妇 在线观看| 欧美乱码精品一区二区三区| 黄色怎么调成土黄色| 一级毛片电影观看| 亚洲第一欧美日韩一区二区三区 | 亚洲综合色网址| 久久久精品国产亚洲av高清涩受| tocl精华| 久久精品成人免费网站| 男女免费视频国产| 90打野战视频偷拍视频| 欧美黑人欧美精品刺激| 日韩精品免费视频一区二区三区| 精品亚洲成国产av| 韩国精品一区二区三区| 日韩免费高清中文字幕av| 精品国产乱子伦一区二区三区| 中文字幕最新亚洲高清| 夫妻午夜视频| 亚洲免费av在线视频| 亚洲国产精品一区二区三区在线| 色94色欧美一区二区| 天堂动漫精品| 免费在线观看完整版高清| kizo精华| 91麻豆精品激情在线观看国产 | 中国美女看黄片| 欧美日韩成人在线一区二区| 欧美日韩视频精品一区| 中国美女看黄片| 夜夜爽天天搞| 国产有黄有色有爽视频| 俄罗斯特黄特色一大片| 极品教师在线免费播放| 亚洲av日韩精品久久久久久密| 久久天堂一区二区三区四区| 亚洲精品久久成人aⅴ小说| 丁香欧美五月| 无遮挡黄片免费观看| 自线自在国产av| 午夜视频精品福利| 悠悠久久av| 黄网站色视频无遮挡免费观看| 一二三四在线观看免费中文在| 下体分泌物呈黄色| 老熟妇乱子伦视频在线观看| 一本大道久久a久久精品| 国产亚洲精品一区二区www | 色视频在线一区二区三区| 国产在线精品亚洲第一网站| 亚洲国产av影院在线观看| 波多野结衣一区麻豆| 欧美日韩一级在线毛片| 久久精品成人免费网站| 一级,二级,三级黄色视频| 欧美精品一区二区大全| 亚洲七黄色美女视频| 51午夜福利影视在线观看| 男女下面插进去视频免费观看| 一级,二级,三级黄色视频| 一边摸一边抽搐一进一小说 | 高清黄色对白视频在线免费看| 亚洲性夜色夜夜综合| 51午夜福利影视在线观看| 99精国产麻豆久久婷婷| 啪啪无遮挡十八禁网站| 视频在线观看一区二区三区| 极品教师在线免费播放| 亚洲性夜色夜夜综合| 丝袜美腿诱惑在线| 免费观看人在逋| 男女之事视频高清在线观看| 狠狠狠狠99中文字幕| 亚洲精品中文字幕一二三四区 | 日日摸夜夜添夜夜添小说| 久久国产亚洲av麻豆专区| 亚洲国产欧美网| 99九九在线精品视频| 亚洲av片天天在线观看| 久久精品国产综合久久久| 国产精品一区二区精品视频观看| 不卡av一区二区三区| 久久久久网色| 国产老妇伦熟女老妇高清| 变态另类成人亚洲欧美熟女 | 99国产精品99久久久久| 亚洲欧美一区二区三区久久| 精品卡一卡二卡四卡免费| 久久精品亚洲精品国产色婷小说| 色播在线永久视频| 夜夜骑夜夜射夜夜干| 岛国在线观看网站| 国产精品久久久久久精品电影小说| 亚洲欧美精品综合一区二区三区| 少妇 在线观看| 精品国产超薄肉色丝袜足j| 少妇粗大呻吟视频| 国产在线一区二区三区精| 国产一区有黄有色的免费视频| 亚洲第一青青草原| 五月开心婷婷网| 精品人妻熟女毛片av久久网站| 人人妻人人澡人人爽人人夜夜| 狠狠狠狠99中文字幕| 国产三级黄色录像| 久久国产精品大桥未久av| 国产伦人伦偷精品视频| 欧美精品一区二区大全| 亚洲天堂av无毛| e午夜精品久久久久久久| 国产精品 欧美亚洲| 日日夜夜操网爽| 两性午夜刺激爽爽歪歪视频在线观看 | 男女边摸边吃奶| 欧美日韩福利视频一区二区| 日韩中文字幕视频在线看片| 搡老乐熟女国产| 男男h啪啪无遮挡| 欧美激情久久久久久爽电影 | 亚洲三区欧美一区| 国产精品久久久久久精品古装| 韩国精品一区二区三区| 日本欧美视频一区| 欧美午夜高清在线| 女人久久www免费人成看片| 欧美日韩亚洲综合一区二区三区_| 国产成人精品久久二区二区91| 汤姆久久久久久久影院中文字幕| 99精品久久久久人妻精品| 一本—道久久a久久精品蜜桃钙片| 美女扒开内裤让男人捅视频| 国产一区二区 视频在线| 午夜日韩欧美国产| 激情在线观看视频在线高清 | 亚洲色图综合在线观看| 男男h啪啪无遮挡| 女同久久另类99精品国产91| 男人舔女人的私密视频| 男女午夜视频在线观看| 一区二区日韩欧美中文字幕| 国产亚洲欧美在线一区二区| 国产精品久久久久久人妻精品电影 | 免费不卡黄色视频| 91大片在线观看| 午夜福利影视在线免费观看| 麻豆成人av在线观看| www.自偷自拍.com| 久久亚洲精品不卡| 国产在线视频一区二区| 久久精品人人爽人人爽视色| 国产福利在线免费观看视频| 日本av免费视频播放| 日本撒尿小便嘘嘘汇集6| 欧美久久黑人一区二区| 国产成+人综合+亚洲专区| 在线观看免费视频日本深夜| 欧美 日韩 精品 国产| 国产免费av片在线观看野外av| 久久亚洲真实| 在线观看免费午夜福利视频| 一本—道久久a久久精品蜜桃钙片| 黄色a级毛片大全视频| 精品少妇内射三级| 午夜91福利影院| 亚洲精品一卡2卡三卡4卡5卡| 十八禁高潮呻吟视频| 少妇被粗大的猛进出69影院| 女人久久www免费人成看片| 国产精品久久久久久人妻精品电影 | 大陆偷拍与自拍| 日韩视频一区二区在线观看| 美女高潮到喷水免费观看| 狠狠狠狠99中文字幕| 午夜精品久久久久久毛片777| 日韩中文字幕视频在线看片| 怎么达到女性高潮| 亚洲专区国产一区二区| 亚洲专区中文字幕在线| 久久狼人影院| 亚洲人成77777在线视频| 一区在线观看完整版| 国产男女内射视频| 国产成人免费无遮挡视频| 亚洲专区字幕在线| 国产精品久久久久久精品古装| 欧美在线黄色| 久久精品人人爽人人爽视色| 麻豆av在线久日| 久久精品国产99精品国产亚洲性色 | 狠狠精品人妻久久久久久综合| 久久天堂一区二区三区四区| 亚洲欧美一区二区三区黑人| 亚洲人成电影免费在线| av又黄又爽大尺度在线免费看| 色视频在线一区二区三区| 一级a爱视频在线免费观看| 久久久国产欧美日韩av| 色94色欧美一区二区| 69精品国产乱码久久久| √禁漫天堂资源中文www| 亚洲欧美一区二区三区久久| 欧美日韩黄片免| 一区福利在线观看| 日韩熟女老妇一区二区性免费视频| 国产精品 国内视频| 久久这里只有精品19| 欧美国产精品一级二级三级| 欧美人与性动交α欧美软件| 日本五十路高清| 久久久国产精品麻豆| 久久久国产成人免费| 男女高潮啪啪啪动态图| 在线 av 中文字幕| 免费看a级黄色片| 国产精品九九99| 久久午夜亚洲精品久久| 成在线人永久免费视频| 国产熟女午夜一区二区三区| 国产精品一区二区在线不卡| 九色亚洲精品在线播放| 午夜福利欧美成人| 日本a在线网址| 一区二区av电影网| 啦啦啦在线免费观看视频4| 亚洲精品中文字幕在线视频| 亚洲成人国产一区在线观看| 大型av网站在线播放| 99热网站在线观看| 日日爽夜夜爽网站| 精品一区二区三区视频在线观看免费 | 丰满饥渴人妻一区二区三| 精品视频人人做人人爽| 极品教师在线免费播放| 操出白浆在线播放| 淫妇啪啪啪对白视频| 黄色成人免费大全| 欧美在线黄色| 中文字幕人妻丝袜制服| 人人妻人人澡人人看| 看免费av毛片| 国产亚洲一区二区精品| 午夜福利乱码中文字幕| 亚洲欧美一区二区三区黑人| av网站在线播放免费| 亚洲午夜理论影院| 国产欧美日韩一区二区三区在线| 精品少妇黑人巨大在线播放| 亚洲色图 男人天堂 中文字幕| 高潮久久久久久久久久久不卡| 午夜两性在线视频| 99re在线观看精品视频| 久久中文字幕人妻熟女| 黄色片一级片一级黄色片| 亚洲精品av麻豆狂野| 在线观看免费视频日本深夜| 欧美激情 高清一区二区三区| 男女下面插进去视频免费观看| 亚洲免费av在线视频| netflix在线观看网站| 嫩草影视91久久| 亚洲精品国产精品久久久不卡| 欧美日韩视频精品一区| 91老司机精品| 超碰97精品在线观看| 亚洲av美国av| 亚洲五月婷婷丁香| 91大片在线观看| 国产精品亚洲一级av第二区| 亚洲精品久久成人aⅴ小说| 国产成人精品无人区| 老司机午夜福利在线观看视频 | 999久久久精品免费观看国产| 亚洲,欧美精品.| 超色免费av| 成人影院久久| 中文亚洲av片在线观看爽 | 另类亚洲欧美激情| 成年人黄色毛片网站| 黑人欧美特级aaaaaa片| 少妇 在线观看| 亚洲av美国av| 日韩有码中文字幕| 91九色精品人成在线观看| 色在线成人网| 欧美日韩亚洲综合一区二区三区_| 亚洲精品乱久久久久久| 99国产精品一区二区三区| tube8黄色片| 久久99一区二区三区| 欧美另类亚洲清纯唯美| 在线观看66精品国产| 人妻一区二区av| 麻豆国产av国片精品| 99久久99久久久精品蜜桃| 欧美av亚洲av综合av国产av| 精品福利永久在线观看| 国产人伦9x9x在线观看| 国产成人欧美| 亚洲av日韩精品久久久久久密| 精品一区二区三区四区五区乱码| 99国产精品一区二区三区| 另类亚洲欧美激情| 国产熟女午夜一区二区三区| 久久久久精品国产欧美久久久| 欧美激情久久久久久爽电影 | 99国产极品粉嫩在线观看| 国产有黄有色有爽视频| √禁漫天堂资源中文www| 少妇 在线观看| 亚洲精品美女久久久久99蜜臀| 欧美日韩福利视频一区二区| 亚洲成人手机| 在线观看人妻少妇| 亚洲七黄色美女视频| 夫妻午夜视频| 一区二区三区激情视频| 久久久水蜜桃国产精品网| 久久这里只有精品19| 无限看片的www在线观看| 美女午夜性视频免费| 欧美精品人与动牲交sv欧美| 国产高清国产精品国产三级| 不卡一级毛片| 90打野战视频偷拍视频| 亚洲成国产人片在线观看| 欧美日韩av久久| 精品乱码久久久久久99久播| 国产欧美日韩综合在线一区二区| 国产成人精品久久二区二区免费| 人人妻,人人澡人人爽秒播| 天天操日日干夜夜撸| 淫妇啪啪啪对白视频| 韩国精品一区二区三区| av超薄肉色丝袜交足视频| 欧美精品av麻豆av| 大型黄色视频在线免费观看| 免费女性裸体啪啪无遮挡网站| 久久久精品94久久精品| 丝袜在线中文字幕| 久久中文字幕人妻熟女| 午夜成年电影在线免费观看| 国产成人欧美| 中文字幕人妻丝袜制服| 免费观看av网站的网址| www.熟女人妻精品国产| 亚洲全国av大片| 久久久久久久精品吃奶| 午夜免费鲁丝| 波多野结衣av一区二区av| 日韩人妻精品一区2区三区| 免费一级毛片在线播放高清视频 | 18在线观看网站| 黄色a级毛片大全视频| 精品亚洲乱码少妇综合久久| 69av精品久久久久久 | 国产精品香港三级国产av潘金莲| 久久精品成人免费网站| 国精品久久久久久国模美| 国产成人系列免费观看| tocl精华| 欧美 亚洲 国产 日韩一| 久久毛片免费看一区二区三区| e午夜精品久久久久久久| 麻豆乱淫一区二区| 黄色视频,在线免费观看| 久久午夜综合久久蜜桃| 巨乳人妻的诱惑在线观看| 久久精品成人免费网站| av国产精品久久久久影院| 国产成人系列免费观看| 超色免费av| 王馨瑶露胸无遮挡在线观看| 精品一品国产午夜福利视频| 三级毛片av免费| 国产精品99久久99久久久不卡| 天堂动漫精品| 首页视频小说图片口味搜索| 日韩中文字幕欧美一区二区| 国产成人精品在线电影| 欧美日韩亚洲国产一区二区在线观看 | 国产有黄有色有爽视频| 久久午夜综合久久蜜桃| 日本五十路高清| 国产成人影院久久av| 黑人操中国人逼视频| 国产精品国产av在线观看| 午夜老司机福利片| 变态另类成人亚洲欧美熟女 | 美女高潮到喷水免费观看| 国产亚洲欧美精品永久| 久久久久久久大尺度免费视频| 黄色视频,在线免费观看| 欧美大码av| 午夜福利视频在线观看免费| 国产成人影院久久av| 一区二区三区乱码不卡18| 国产伦理片在线播放av一区| 在线av久久热| 美女视频免费永久观看网站| 最近最新中文字幕大全免费视频| netflix在线观看网站| videosex国产| 免费一级毛片在线播放高清视频 | 黄片小视频在线播放| 大片电影免费在线观看免费| 男女午夜视频在线观看| 成年人黄色毛片网站| 曰老女人黄片| 大陆偷拍与自拍| 久久99热这里只频精品6学生| avwww免费| 国产区一区二久久| 国产一区二区三区视频了| 亚洲av日韩在线播放| 丝袜美足系列| 十八禁网站免费在线| 夫妻午夜视频| 亚洲成人免费av在线播放| 操出白浆在线播放| 黄网站色视频无遮挡免费观看| 国产成人精品无人区| 亚洲欧美一区二区三区久久| 一二三四社区在线视频社区8| 男女高潮啪啪啪动态图| 亚洲欧美色中文字幕在线| 日本一区二区免费在线视频| 在线观看www视频免费| 夜夜爽天天搞| 又黄又粗又硬又大视频| 91成年电影在线观看| 精品国产乱子伦一区二区三区| 少妇被粗大的猛进出69影院| 午夜激情久久久久久久| 亚洲少妇的诱惑av| 亚洲熟女精品中文字幕| 一边摸一边做爽爽视频免费| 亚洲av日韩在线播放| 国产亚洲精品一区二区www | 国产淫语在线视频| 久久这里只有精品19| 午夜视频精品福利| 青草久久国产| 国产精品亚洲一级av第二区| 久久99一区二区三区| 在线观看舔阴道视频| 99国产精品免费福利视频| 黑人猛操日本美女一级片| 免费看a级黄色片| 操出白浆在线播放| 在线观看www视频免费| 久久免费观看电影| 亚洲va日本ⅴa欧美va伊人久久| 国产成人精品在线电影| 久久99热这里只频精品6学生| 欧美午夜高清在线| 国产男女内射视频| 少妇精品久久久久久久| 亚洲人成伊人成综合网2020| 超碰97精品在线观看| 又大又爽又粗| 午夜激情av网站| 久久99一区二区三区| 国产在视频线精品| 国产亚洲欧美在线一区二区| 黄色怎么调成土黄色| 宅男免费午夜| 一级毛片电影观看| av在线播放免费不卡| 老司机午夜福利在线观看视频 | 国产亚洲欧美在线一区二区| 亚洲情色 制服丝袜| 国产一卡二卡三卡精品| 在线播放国产精品三级| 在线观看免费视频网站a站| 自拍欧美九色日韩亚洲蝌蚪91| 日韩成人在线观看一区二区三区| 亚洲免费av在线视频| 老熟女久久久| 国产成人av教育| 成人国产一区最新在线观看| 欧美日韩一级在线毛片| 丝袜在线中文字幕| 波多野结衣一区麻豆| 美女视频免费永久观看网站| 精品国产超薄肉色丝袜足j| 日韩大码丰满熟妇| 日韩中文字幕欧美一区二区| 亚洲五月婷婷丁香| 精品一区二区三区视频在线观看免费 | 日本a在线网址| 欧美性长视频在线观看| 亚洲精品中文字幕一二三四区 | 亚洲av电影在线进入| 亚洲成人手机| 国产免费现黄频在线看| 色播在线永久视频| 国产精品一区二区在线观看99| 真人做人爱边吃奶动态| 国产午夜精品久久久久久| 精品少妇久久久久久888优播| 天堂动漫精品| 精品国内亚洲2022精品成人 | 日韩中文字幕欧美一区二区| 高清毛片免费观看视频网站 | 少妇被粗大的猛进出69影院| 免费av中文字幕在线| 国产免费av片在线观看野外av| www.熟女人妻精品国产| 久久毛片免费看一区二区三区| 亚洲精品国产色婷婷电影| 他把我摸到了高潮在线观看 | 男女无遮挡免费网站观看| 国产成人啪精品午夜网站| 考比视频在线观看| 国产高清videossex| 亚洲成人国产一区在线观看| 国产在线精品亚洲第一网站| 欧美黑人欧美精品刺激| 黄色怎么调成土黄色| 久久久水蜜桃国产精品网| 美女福利国产在线| 国产亚洲精品久久久久5区|